All In Biotech

Drug Trial Radar · NCT00127179

A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia

Last checked: Nov 19, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Jan 1, 2004

Primary completion

Jul 1, 2005

Study completion Jul 25, 2005

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 50 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • MK0906, finasteride / Duration of Treatment: 48 weeksDrug

  • Comparator: placebo / Duration of Treatment: 48 weeksDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the International Prostate Symptom Score

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.